F M Grace1, B Davies. 1. Department of Health and Exercise Science, School of Applied Sciences, University of Glamorgan, Pontypridd, Wales, UK. fgrace2@glam.ac.uk
Abstract
OBJECTIVE: To examine levels of C reactive protein in users of anabolic androgenic steroids (AAS) compared with age matched control groups consisting of AAS using (but abstinent)/resistance trained and non-drug using/sedentary controls. METHOD: Subjects included AAS using bodybuilders (n = 10); bodybuilders who denied AAS use (n = 10); sedentary controls (n = 8). Venous blood was sampled, from which serum concentrations of C reactive protein, male sex hormones, and cardiac troponin T were determined. RESULTS: A significantly altered hormonal profile in the AAS using group provided indirect confirmation of AAS use. C reactive protein concentrations were significantly (p<0.05) higher in the AAS using bodybuilders. There was no relation between C reactive protein and cardiac troponin T. CONCLUSION: AAS using bodybuilders had significantly higher C reactive protein concentrations, indicating a greater propensity to develop peripheral arterial disease.
OBJECTIVE: To examine levels of C reactive protein in users of anabolic androgenic steroids (AAS) compared with age matched control groups consisting of AAS using (but abstinent)/resistance trained and non-drug using/sedentary controls. METHOD: Subjects included AAS using bodybuilders (n = 10); bodybuilders who denied AAS use (n = 10); sedentary controls (n = 8). Venous blood was sampled, from which serum concentrations of C reactive protein, male sex hormones, and cardiac troponin T were determined. RESULTS: A significantly altered hormonal profile in the AAS using group provided indirect confirmation of AAS use. C reactive protein concentrations were significantly (p<0.05) higher in the AAS using bodybuilders. There was no relation between C reactive protein and cardiac troponin T. CONCLUSION: AAS using bodybuilders had significantly higher C reactive protein concentrations, indicating a greater propensity to develop peripheral arterial disease.
Authors: Richard D Rothman; Rory B Weiner; Harrison Pope; Gen Kanayama; Adolph M Hutter; Michael A Fifer; G William Dec; Aaron L Baggish Journal: BMJ Case Rep Date: 2011-08-17
Authors: P Borrione; F Pigozzi; G Massazza; H Schonhuber; G Viberti; P Paccotti; A Angeli Journal: J Endocrinol Invest Date: 2007-05 Impact factor: 4.256